New pill ZX-8177 enters human trials for Hard-to-Treat cancers
NCT ID NCT07310134
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This early-stage trial tests a new oral drug called ZX-8177 in about 80 Chinese adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tumors. Participants take the pill twice daily in one of five dose levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai GoBroad Cancer Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZX-8177 tablets
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 80 participants, so it is too soon to know if ZX-8177 is safe or effective. Many cancer drugs fail in early testing.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.